IDO小分子抑制剂的临床研究进展
[13] Crosignani S， Bingham P， Bottemanne P， et al. Discovery of a novel and selective indoleamine 2，3-dioxygenase (IDO-1) inhibitor 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2，5-dione(EOS200271/PF-06840003) and its characterization as a potential clinical candidate[J]. J Med Chem， 2017， 60(23)： 9617-9629.
[14] Gomes B， Driessens G， Bartlett D， et al. Characterization of the selective indoleamine 2，3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy[J]. Mol Cancer Ther， 2018， 17(12)： 2530-2542.
[15] Rixe O， George T， Soares H， et al. A phase Ⅰ clinical trial of NLG802， a prodrug of indoximod with enhanced pharmacokinetic properties[EB/OL]. (2018-11-07)[2019-02-18]. http：//investors.linkp.com/static-files/6392cf01-5ffb-48e5-8334-218d501d2c46.
[16] Yap TA， Sahebjam S， Hong DS， et al. First-in-human study of KHK2455， a long-acting， potent and selective indoleamine 2，3-dioxygenase 1 (IDO-1) inhibitor， in combination with mogamulizumab (Moga)， an anti-CCR4 monoclonal antibody， in patients (pts) with advanced solid tumors[J]. J Clin Oncol， 2018， 36(15 Suppl)： 3040., 百拇医药(王倩)
[14] Gomes B， Driessens G， Bartlett D， et al. Characterization of the selective indoleamine 2，3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy[J]. Mol Cancer Ther， 2018， 17(12)： 2530-2542.
[15] Rixe O， George T， Soares H， et al. A phase Ⅰ clinical trial of NLG802， a prodrug of indoximod with enhanced pharmacokinetic properties[EB/OL]. (2018-11-07)[2019-02-18]. http：//investors.linkp.com/static-files/6392cf01-5ffb-48e5-8334-218d501d2c46.
[16] Yap TA， Sahebjam S， Hong DS， et al. First-in-human study of KHK2455， a long-acting， potent and selective indoleamine 2，3-dioxygenase 1 (IDO-1) inhibitor， in combination with mogamulizumab (Moga)， an anti-CCR4 monoclonal antibody， in patients (pts) with advanced solid tumors[J]. J Clin Oncol， 2018， 36(15 Suppl)： 3040., 百拇医药(王倩)